Home

ATG4A (human)

Overview ATG4A Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes. Preferred substrate is GABARAPL2 followed by MAP1LC3A and GABARAP. Widely expressed, at a low level, and the highest expression is observed in skeletal muscle and brain. Also detected in fetal liver. Inhibited by N-ethylmaleimide. Belongs to the peptidase C54 family. 4 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB. Protein type: Microtubule binding protein; Protease; EC 3.4.22.-; Autophagy Cellular Component: cytoplasm Molecular Function: cysteine-type peptidase activity Biological Process: protein transport; autophagy; proteolysis Reference #:  Q8WYN0 (UniProtKB) Alt. Names/Synonyms: APG4 autophagy 4 homolog A; APG4A; ATG4 autophagy related 4 homolog A (S. cerevisiae); ATG4A; AUT-like 2 cysteine endopeptidase; AUT-like 2, cysteine endopeptidase; AUTL2; autophagin 2; Autophagin-2; Autophagy-related cysteine endopeptidase 2; Autophagy-related protein 4 homolog A; Cysteine protease ATG4A; hAPG4A Gene Symbols: ATG4A Molecular weight: 45,378 Da Basal Isoelectric point: 4.93  Predict pI for various phosphorylation states CST Pathways:  Autophagy Signaling Protein-Specific Antibodies or siRNAs from Cell Signaling Technology®

Select Structure to View Below ATG4A 2P82 - A/D/C/B=23-359 (human)

STRING  |  Scansite  |  Phospho.ELM  |  Pfam  |  RCSB PDB 2FUY 2P82  |  ENZYME  |  Phospho3D  |  DISEASE  |  Source  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene

	Modification Sites and Domains

	Modification Sites in Parent Protein, Orthologs, and Isoforms

SS  SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.	MS  MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.			human
0	1		Y111-p	QKEQPKEyQRILQCF

	mouse
Y111	QKEQPKEYQRILQCF

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E Produced by 3rd Millennium  |  Design by Digizyme ©2003-2013 Cell Signaling Technology, Inc.